Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03386890
Other study ID # XMLX201606
Secondary ID
Status Recruiting
Phase N/A
First received December 6, 2017
Last updated December 28, 2017
Start date December 2015
Est. completion date December 31, 2018

Study information

Verified date December 2017
Source Beijing Friendship Hospital
Contact Qianyi Wang
Phone 86-13811629824
Email wangqy1001@hotmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China. As NAFLD can progress to Non-alcoholic steatohepatitis (NASH), cirrhosis and Hepatocarcinoma, the identification and quantitative evaluation of liver steatosis and its dynamic changes are crucial. While liver biopsy is still the gold standard in the diagnosis of NAFLD, its application is limited because of the invasive procedure.The Transient Elastography(TE) combined with the Controlled Attenuation Parameter(CAP) is a new non-invasive diagnostic method for fatty liver and liver fibrosis.

In order to evaluate the diagnostic value of non-invasive assessment for the degree of liver steatosis and staging liver fibrosis, this non-invasive method will be assessed by the golden standard of liver biopsy among 400 NAFLD patients.The treatment protocols will be decided by doctor and patient both (treatment protocols and medicine are not required). Blood routine, blood biochemistry, abdominal ultrasound and Transient Elastography(TE) combined with the Controlled Attenuation Parameter(CAP) are detected during the follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date December 31, 2018
Est. primary completion date December 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age:18=,=65

- Gender:male or female

- NAFLD patient,agree with the paracentesis of liver tissue

- Regular follow-up

- Signing the Informed Consent Form

Exclusion Criteria:

- Hepatic decompensation:Including cirrhotic complications,such as ascites,hepatic encephalopathy,digestive tract bleeding,hepatorenal syndrome,spontaneous bacterial peritonitis,and HCC.

- Complications of HBV,HCV,HIV.Complications of alcoholic liver disease,autoimmune liver disease,hereditary metabolic liver disease, drug-induced liver disease and other chronic liver disease.

- AFP>100ng/ml and imaging indicates malignant occupying.Or AFP still>100ng/ml within 3 months.

- Creatinine was 1.5 times higher than the upper limit of the normal value.

- Combined with other malignant tumors(except those cured).

- Serious diseases of heart, lung, kidney, brain, blood and other important organs with dysfunction.

- severe neurological and psychiatric diseases (such as epilepsy, depression, mania, schizophrenia, etc.)

- Pregnant women and breast-feeding women.

- The researchers consider that it is not suitable for the patients to participate in this study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Friendship Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Liver Biopsy liver histological section 1 year
Primary CAP Controlled Attenuation Parameter 1 year
Primary TE Transient Elastography 1 year
Secondary Blood routine test Blood routine test 1 year
Secondary liver biochemistry test liver biochemistry test 1 year
Secondary abdominal ultrasound abdominal ultrasound 1 year
Secondary electrolyte electrolyte 1 year
Secondary blood glucose blood glucose 1 year
Secondary blood lipid blood lipid 1 year
Secondary uric acid uric acid 1 year
Secondary kidney function test kidney function test 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Recruiting NCT06098417 - Biomarkers in the Diagnosis and Prognosis of NAFLD
Not yet recruiting NCT03623360 - Functional MRI to Determine Severity of Cirrhosis
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Not yet recruiting NCT01133184 - Improved Prevention of Perinatal Hepatitis B Transmission Phase 4
Completed NCT00043303 - Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis Phase 2
Completed NCT03872024 - Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients N/A
Recruiting NCT05912179 - Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
Recruiting NCT04533828 - 68Ga-FAPI PET/CT in Liver Fibrosis Patients Early Phase 1
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Recruiting NCT03277651 - Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension N/A
Completed NCT01707472 - Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis Phase 2
Completed NCT01810458 - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed NCT02060162 - Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Completed NCT00049842 - Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) Phase 3
Recruiting NCT06063785 - Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis